Patents by Inventor Eric Campeau

Eric Campeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for the treatment of triple-negative breast cancer
    Patent number: 11607405
    Abstract: The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 21, 2023
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Eric Campeau, Laura Tsujikawa, Sanjay Lakhotia
  • COMBINATION THERAPY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20220117942
    Abstract: The invention provides methods for treating prostate cancer, including metastatic castration-resistant prostate cancer, comprising administering to a subject in need thereof a BET bromodomain inhibitor in combination with a second agent.
    Type: Application
    Filed: September 13, 2019
    Publication date: April 21, 2022
    Applicant: Zenith Epigenetics Ltd.
    Inventors: Sarah Christine ATTWELL, Eric CAMPEAU, Sanjay LAKHOTIA
  • COMBINATION THERAPY FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20220062246
    Abstract: The invention provides methods for treating triple negative breast cancer (TNBC), by co-administration of a BET bromodomain inhibitor selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo[4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof, and a second therapeutic agent to a subject in need thereof. The second therapeutic agent can be a PARP inhibitor, such as, e.g., talazoparib, olaparib or veliparib.
    Type: Application
    Filed: September 13, 2019
    Publication date: March 3, 2022
    Inventors: Eric CAMPEAU, Laura TSUJIKAWA, Sanjay LAKHOTIA
  • COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-RECEPTOR POSITIVE BREAST CANCER
    Publication number: 20220047563
    Abstract: Methods for treating estrogen receptor positive (ER+) breast cancer, comprising administering to a subject in need thereof, a BET bromodomain inhibitor in combination with a second agent, selected from a selective-estrogen receptor degrader (SERD), a selective-estrogen receptor modulator (SERM) and a selective CDK4/6 inhibitor. The BET bromodomain inhibitor is selected from 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-N-methyl-1H-imidazo[4,5-b]pyridin-2-amine (Compound I), 1-benzyl-6-(3,5-dimethylisoxazol-4-yl)-1H-imidazo [4,5-b]pyridin-2-amine, and pharmaceutically acceptable salts/co-crystals thereof.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 17, 2022
    Inventors: Eric CAMPEAU, Olesya KHARENKO, Edward T.H. VAN DER HORST
  • Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
    Publication number: 20040073018
    Abstract: The invention features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects or cardiovascular disease. The invention also features therapeutic methods for reducing the risk of neural tube defects, colon cancers and related cancers. Also provided are the sequences of the human methionine synthase gene and protein and compounds and kits for performing the methods of the invention.
    Type: Application
    Filed: June 27, 2003
    Publication date: April 15, 2004
    Inventors: Roy A. Gravel, Rima Rozen, Daniel LeClerc, Philippe Goyette, Eric Campeau
  • Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
    Patent number: 6703197
    Abstract: The invention features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects or cardiovascular disease. The invention also features therapeutic methods for reducing the risk of neural tube defects, colon cancers and related cancers. Also provided are the sequences of the human methionine synthase gene and protein and compounds and kits for performing the methods of the invention.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 9, 2004
    Assignee: Martinex R&D, Inc.
    Inventors: Roy A. Gravel, Rima Rozen, Daniel LeClerc, Philippe Goyette, Eric Campeau